We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Accelerant Stock a Buy After Its Sharp Pullback and Nearly 16X P/E?
Read MoreHide Full Article
Key Takeaways
ARX grew first-quarter 2026 revenue 57% and raised its adjusted EBITDA outlook to at least $285 million.
ARX is shifting toward fee-based earnings, with third-party premiums reaching 41% of exchange premiums.
ARX trades below industry P/E, but concentration, cash flow timing and underwriting margins remain risks.
Accelerant Holdings (ARX - Free Report) has retreated sharply from its highs, but the operating story remains intact. Revenue growth, fee-based earnings and third-party platform participation still point to a business gaining scale.
The question is whether the lower stock price offsets the risks. For now, ARX looks more like a selective growth idea than an obvious buy-the-dip call. Over the year-to-date period, its shares have declined 23.6%, underperforming the industry’s fall of 5.5%.
Image Source: Zacks Investment Research
ARX Valuation Looks Lower
ARX trades at 15.99X forward 12-month earnings, below the industry average at 16.50X, the sector at 16.29X and the S&P 500 at 21.03X.
Image Source: Zacks Investment Research
That discount helps after the stock’s pullback. Still, the $15 price target versus the $13.07 share price suggests upside, not a dramatic rerating case.
Accelerant Delivers Strong Revenue and EBITDA Growth
Accelerant’s first-quarter 2026 revenues rose 57% year over year to $273.2 million. Adjusted earnings reached 17 cents per share, while adjusted EBITDA climbed 70% to $66.1 million.
The fee-led side is carrying much of the argument. Management raised its 2026 adjusted EBITDA outlook to at least $285 million, including at least $276 million from fee-based businesses.
Why ARX Earnings Quality Is Improving
The mix shift matters because ARX wants to earn more from platform fees and less from retained underwriting risk. Third-party direct written premiums reached 41% of exchange written premiums in the quarter.
Exchange Services also offers attractive economics, with margins expected near 70%. Management expects net premium retention around 10% for 2026, reinforcing the capital-light direction.
Accelerant Risks to Watch
Hadron concentration remains a key watch item, even after improvement. Fronting arrangements must also ramp through 2026 and 2027 before investors can fully credit the diversification story.
Cash flow is another offset. Operating cash flow can swing with reinsurance timing, and the Underwriting segment posted only about a 4% adjusted EBITDA margin in the first quarter.
ARX Stock Sits Between Growth and Caution
ARX has a credible growth setup: higher third-party participation, stronger take rates, growing members and a more fee-heavy earnings base. That separates it from a pure underwriting story.
Still, the current fiscal year earnings estimate implies a decline from the prior year. Ryan Specialty Holdings, Inc. (RYAN - Free Report) offers another way to track specialty insurance distribution and underwriting-management demand, while Brown & Brown, Inc. (BRO - Free Report) provides investors with a broader insurance brokerage reference point.
How ARX Ratings Fit This Setup
The bottom line: ARX is improving operationally, but the stock is not a clean bargain. The growth signals are real, while concentration, cash timing and uneven underwriting profitability keep the risk-reward balanced.
View the Zacks #1 Rank List
Image: Bigstock
Is Accelerant Stock a Buy After Its Sharp Pullback and Nearly 16X P/E?
Key Takeaways
Accelerant Holdings (ARX - Free Report) has retreated sharply from its highs, but the operating story remains intact. Revenue growth, fee-based earnings and third-party platform participation still point to a business gaining scale.
The question is whether the lower stock price offsets the risks. For now, ARX looks more like a selective growth idea than an obvious buy-the-dip call. Over the year-to-date period, its shares have declined 23.6%, underperforming the industry’s fall of 5.5%.
ARX Valuation Looks Lower
ARX trades at 15.99X forward 12-month earnings, below the industry average at 16.50X, the sector at 16.29X and the S&P 500 at 21.03X.
That discount helps after the stock’s pullback. Still, the $15 price target versus the $13.07 share price suggests upside, not a dramatic rerating case.
Accelerant Delivers Strong Revenue and EBITDA Growth
Accelerant’s first-quarter 2026 revenues rose 57% year over year to $273.2 million. Adjusted earnings reached 17 cents per share, while adjusted EBITDA climbed 70% to $66.1 million.
The fee-led side is carrying much of the argument. Management raised its 2026 adjusted EBITDA outlook to at least $285 million, including at least $276 million from fee-based businesses.
Why ARX Earnings Quality Is Improving
The mix shift matters because ARX wants to earn more from platform fees and less from retained underwriting risk. Third-party direct written premiums reached 41% of exchange written premiums in the quarter.
Exchange Services also offers attractive economics, with margins expected near 70%. Management expects net premium retention around 10% for 2026, reinforcing the capital-light direction.
Accelerant Risks to Watch
Hadron concentration remains a key watch item, even after improvement. Fronting arrangements must also ramp through 2026 and 2027 before investors can fully credit the diversification story.
Cash flow is another offset. Operating cash flow can swing with reinsurance timing, and the Underwriting segment posted only about a 4% adjusted EBITDA margin in the first quarter.
ARX Stock Sits Between Growth and Caution
ARX has a credible growth setup: higher third-party participation, stronger take rates, growing members and a more fee-heavy earnings base. That separates it from a pure underwriting story.
Still, the current fiscal year earnings estimate implies a decline from the prior year. Ryan Specialty Holdings, Inc. (RYAN - Free Report) offers another way to track specialty insurance distribution and underwriting-management demand, while Brown & Brown, Inc. (BRO - Free Report) provides investors with a broader insurance brokerage reference point.
How ARX Ratings Fit This Setup
The bottom line: ARX is improving operationally, but the stock is not a clean bargain. The growth signals are real, while concentration, cash timing and uneven underwriting profitability keep the risk-reward balanced.
ARX currently carries a Zacks Rank #2 (Buy). Its Momentum Score of A and Growth Score of B support the case for constructive near-term and growth characteristics, while its Value Score of C suggests the shares are not obviously mispriced on traditional value measures. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.